The Sep 4–5 window produced 2 disclosed deals, 0 FDA approvals and 12 Phase 2/3 readouts due within 90 days; Novartis also reported a Phase 3 miss for its Lp(a) program. The pattern: both deals involve China-originated assets, accounting for $851M.
TL;DR — Two disclosed deals ($771M GLP-1 commercialization, $80M financing), a Phase 3 miss for Novartis’s Lp(a) program, zero FDA approvals and 12 Phase 2/3 readouts due within 90 days. China-originated assets captured 100% of the window’s disclosed dollars ($851M). Caveat: the disclosed-value sample is two deals and the historical comp base is also two deals — directional only.
Deals
| Company | Type | Terms (upfront → total) | vs. history | Source |
|---|---|---|---|---|
| Menarini / Gan & Lee | Other | undisclosed → $771M | — | FierceBiotech |
| NeuShen | Financing | undisclosed → $80M | — | Endpoints |
Table 1: Deal events in the collection window (Sep 4–5, 2026), sorted by disclosed total value. “undisclosed” means the source gives no number — we never estimate.
Comp context: the historical comp base holds only 2 deals with disclosed totals (median $666M), so percentiles are unavailable and any comparison is thin-sample. The $771M Menarini-Gan & Lee headline is above that median, but the $80M NeuShen financing is not a comparable license. Both disclosed deals give no upfront split, so headline totals overstate near-term cash.
Figure 1: Largest disclosed deal of the window: $771M — Menarini’s European license of Gan & Lee’s GLP-1 asset.
Approvals
openFDA’s Drugs@FDA feed recorded no approvals in this window — a genuinely quiet two days at the agency, not a gap in coverage.
Readout Calendar
| Primary completion | Phase | Study (sponsor) |
|---|---|---|
| 2026-10-31 | Phase 3 | TAK-788 first-line EGFR exon 20 NSCLC (Takeda) |
| 2026-10-31 | Phase 3 | Capivasertib + fulvestrant, HR+/HER2- breast cancer (AstraZeneca) |
| 2026-12-01 | Phase 3 | Felzartamab in kidney-transplant AMR (Biogen) |
| 2026-12 | Phase 2 | ABBV-RGX-314 gene therapy, nAMD (AbbVie) |
| 2026-10 | Phase 3 | Ervebo/Zabdeno Ebola booster vaccines (Institute of Tropical Medicine, Belgium) |
| 2026-09-30 | Phase 3 | Sindilizumab in resectable lung cancer (Innovent Biologics) |
| 2026-12 | Phase 3 | QLG1091 vs Rybelsus, type 2 diabetes (Qilu Pharmaceutical) |
| 2026-11-30 | Phase 3 | Ferric carboxymaltose in advanced gastric cancer (Asan Medical Center) |
Table 2: Highest-ranked Phase 2/3 primary completions due in the next 90 days (score = phase weight × log enrollment × sponsor factor).
Market Reaction
No qualifying price moves were recorded in the window.
One Take
Every disclosed dollar this window — the $771M Menarini/Gan & Lee GLP-1 deal plus the $80M NeuShen financing — is attached to a China-originated asset, which is 100% of the $851M disclosed total. The $771M headline alone is 91% of that total and sits above a two-deal historical median of $666M, but the comp base is too thin to call the terms rich. My read: China-originated assets continue to absorb the bulk of disclosed BD capital in this window, and Gan & Lee’s European out-license is the clearest data point. Conviction: moderate — this is one two-day window and the sample is tiny. What would change my mind: a sustained run of non-China-originated deals with comparable headline totals, or disclosed upfronts showing the headline totals are mostly back-loaded milestones.
Key takeaways
- China-originated assets took 100% of the window’s disclosed deal dollars ($851M across two transactions).
- Menarini’s $771M Gan & Lee GLP-1 deal is 91% of the disclosed total and exceeds the two-deal historical median of $666M; the sample is thin.
- Both disclosed deals give no upfront split, so headline totals overstate near-term cash.
- No FDA approvals were recorded, while 12 Phase 2/3 readouts are due in the next 90 days, with two Phase 3 studies completing on 2026-10-31.
FAQ
What share of disclosed dollars went to China-originated assets?
100%: the $771M Menarini/Gan & Lee GLP-1 deal and the $80M NeuShen financing sum to $851M. Novartis’s Lp(a) Phase 3 miss is trial news, not a deal, so it carries no deal terms.
How should I read the $771M Menarini-Gan & Lee headline?
It is above the two-deal historical median of $666M, but the comp base is thin and the upfront is undisclosed; headline totals overstate near-term cash.
Which readout matters most in the next 90 days?
By the pack score (phase × enrollment × sponsor), Takeda’s TAK-788 first-line EGFR exon 20 NSCLC Phase 3 and AstraZeneca’s capivasertib+fulvestrant Phase 3 both complete on 2026-10-31.
Sources
- Menarini signs $771M deal to take Gan & Lee GLP-1 to European market — FierceBiotech
- US-China biotech NeuShen gets $80M to develop brain-health drugs — Endpoints News
- Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial — FierceBiotech
- TAK-788 Phase 3 (NCT04129502) — ClinicalTrials.gov
- Capivasertib+fulvestrant Phase 3 (NCT06635447) — ClinicalTrials.gov
- Felzartamab Phase 3 (NCT06685757) — ClinicalTrials.gov
- ABBV-RGX-314 Phase 2 (NCT04704921) — ClinicalTrials.gov
- Ervebo/Zabdeno Ebola booster Phase 3 (NCT06126822) — ClinicalTrials.gov
- Sindilizumab Phase 3 (NCT05116462) — ClinicalTrials.gov
- QLG1091 Phase 3 (NCT07487103) — ClinicalTrials.gov
- Ferric carboxymaltose Phase 3 (NCT05226169) — ClinicalTrials.gov
- Zibotentan/dapagliflozin Phase 2 (NCT06942910) — ClinicalTrials.gov
- Lutetium-177 oxodotreotide Phase 3 (NCT05884255) — ClinicalTrials.gov
All items above are drawn from first-hand public sources — SEC filings, trial registries, and company releases — collected 2026-09-05. Related: Pharma Daily — September 4, 2026.